Portal de Periódicos da CAPES

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor

2021; Springer Nature; Volume: 40; Issue: 8 Linguagem: Inglês

10.1038/s41388-020-01611-6

1476-5594

Joseph E. Grossman, Divya Vasudevan, Cailin E. Joyce, Manuel Hildago,

Immunotherapy and Immune Responses

Table 1 Anti-PD-1 monotherapy approvals with PD-L1 companion diagnostic.Clinical trials for which only PD-L1+ patients were treated Keytruda in 1L NSCLC KEYNOTE-024 Tecentriq in 1L NSCLC IMpower110 Clinical trials for which relatively few PD-L1-patients were assessed Keytruda in chemotherapy-resistant cervical cancer • 16% PD-L1-pts (N = 16) KEYNOTE-158 (Cohort E) Clinical trials demonstrating limited benefit in PD-L1-patients Keytruda in 2L+ esophageal • 1°endpoint met only in PD-L1 selected pts KEYNOTE-181 Keytruda in 1L SCCHN • No benefit vs cetuximab in PD-L1 unselected pts KEYNOTE-048 Keytruda in 1L urothelial cancer • Less benefit vs platinum-based chemo in PD-L1-pts KEYNOTE-052 KEYNOTE-361 Tecentriq in 1L urothelial cancer pts who are ineligible for platinum-based chemo • Less benefit vs platinum-based chemo in PD-L1-pts IMvigor210 IMvigor130